Chang Chia-Ching, Lee Yi-Liang, Yin Chih-Hsiang, Chang Cheng-Chang, Lin Yi-Hsin
Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
National Defense Medical Center, Taipei, Taiwan.
Discov Oncol. 2025 Jul 12;16(1):1322. doi: 10.1007/s12672-025-03120-y.
Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 in managing CRF in gynecologic cancer patients.
This retrospective cohort study was performed at the Department of Obstetrics & Gynecology, Tri-Service General Hospital from December 2015 to December 2022. Of 53 patients included, 40 received PG2 with chemotherapy, while 13 received chemotherapy alone. Outcomes included CRF severity and HRQL, assessed via Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General 7 (FACT-G7), plus safety profiles.
PG2-treated patients showed a statistically significant reduction in CRF severity, as reflected by lower BFI (p < 0.001). The PG2 group showed trends toward improved HRQL and reduced appetite loss, though not statistically significant (p > 0.05). PG2's safety profile aligned with the control group, showing no increase in grade 3/4 toxicities.
The study concludes that PG2 shows promise as an adjunct therapy in the management of CRF among patients with gynecologic cancer receiving chemotherapy. However, the findings highlight the need for additional prospective, randomized controlled trials to rule out the risk of bias and ascertain PG2's full therapeutic potential in oncology supportive care.
癌症相关疲劳（CRF）是接受化疗的妇科癌症患者中常见且使人衰弱的副作用。黄芪多糖（PG2）作为一种免疫调节药物，在缓解CRF方面显示出前景。本研究旨在评估PG2在管理妇科癌症患者CRF方面的有效性。
本回顾性队列研究于2015年12月至2022年12月在三军总医院妇产科进行。纳入的53例患者中，40例在化疗时接受了PG2，而13例仅接受化疗。结局包括CRF严重程度和健康相关生活质量，通过简明疲劳量表（BFI）和癌症治疗功能评估通用版7（FACT-G7）进行评估，以及安全性概况。
PG2治疗的患者CRF严重程度有统计学显著降低，较低的BFI反映了这一点（p < 0.001）。PG2组在健康相关生活质量改善和食欲减退减少方面有趋势，但无统计学显著性（p > 0.05）。PG2的安全性概况与对照组一致，3/4级毒性未增加。
该研究得出结论，PG2作为辅助治疗在接受化疗的妇科癌症患者CRF管理中显示出前景。然而，研究结果强调需要更多前瞻性、随机对照试验以排除偏倚风险并确定PG2在肿瘤支持治疗中的全部治疗潜力。
